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Abstract 
 
The primary focus of this developmental paper is to evaluate how pharmaceutical organisations 
in the United Kingdom deliver Joint Working initiatives in partnership with the healthcare 
service. Joint Working represents the most formalised and transparent mechanism for 
cooperation between the industry and the National Health Service (NHS). The research 
evaluates the level of capability that organisations ‘desire’ to deliver collaborative initiatives, 
and the degree to which they possess the competencies to deliver them. A pilot study is 
conducted that adopts a mixed method research approach using secondary data and focus group 
analyses, interviews, and a survey. The findings present a comprehensive range of benefits that 
would appear to represent a compelling rationale for enhanced capability in Joint Working 
within the healthcare sector. 
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1. Introduction 
 
Partnerships and collaborations are complex and interesting relationships as organisations react 
to customer demands for greater value and benefit. In many industries the key to success lies 
in the ability to attract and accomplish projects where a number of partners work together 
(Brady & Davies, 2004; Crawford, 2006; Söderlund, 2008; Turner, Ledwith, & Kelly, 2009). 
This research paper reports the findings of a pilot study that examines a specific type of 
collaboration between the pharmaceutical industry and the National Health Service (NHS) in 
the United Kingdom. The Association of the British Pharmaceutical Industry (ABPI), and the 
Department of Health (DOH) use the term Joint Working to describe a particular type of 
undertaking in which the NHS and pharmaceutical organisations pool resources to deliver 
projects designed primarily to improve patient health, whilst also offering benefits to the 
participating parties (ABPI, 2013). This paper explores and evaluates the use and value of Joint 
Working initiatives within the pharmaceutical industry in the United Kingdom (UK). The 
primary aim of this paper is to evaluate the level of capability that an individual organisation 
aspires to within the Joint Working sector, and the degree to which it possesses the project 
management competencies to deliver collaborative initiative of this type. The findings are 
based on an intra-organisation appraisal of desired and current collaborative working 
performance, and provide greater understanding of the capabilities and competencies necessary 
to deliver high quality Joint Working collaborations in partnership with the NHS. 
 
2. Theoretical Background 
 
The pharmaceutical industry in UK is often perceived to be highly profit-centric with a 
reputation blemished by controversies ranging from a disregard for patient welfare (Goldacre, 
2012; Kay, 2010), the misrepresentation of data (Goldacre, 2012; Kay, 2010; Savitz and 
Weber, 2014), and allegations of widespread corruption (Ward, 2014). Against this backdrop 
of scepticism there is a desire within the industry to improve its image as a corporate citizen 
(Savitz and Weber, 2014) and deliver on stakeholder expectations (Wang, 2014). In this 
context, collaborations between the NHS and the pharmaceutical industry - although 
potentially challenging (Evans, 2012) - could offer all participating parties a range of possible 
benefits (Colquhoun, 2012; Farrar, 2012, in ABPI, 2012; Horton, 2009; Whitehead, 2012). In 
recent years the DOH and NHS have proposed a number of policy drivers that have been seen 
as catalysing a greater degree of collaboration between the private and public healthcare 
sectors, (Ham and Murray, 2015), wherein the term ‘collaboration’ most accurately describes 
formal Joint Working initiatives taking place between the NHS and pharmaceutical industry 
with a focus on a collective goal and pooling of resources, and the sharing of risk and reward.   
 
The literature regarding collaborative projects is relatively rich, particularly in the engineering 
and construction industries (Bresnen 2009; Bygballe et al. 2010; Hong et al., 2012; Galliford, 
1998), where various authors discuss the potential virtues and pitfalls inherent within 
partnerships (Bresnen, 2009; Bresnen and Marshall, 2000; Chan et al., 2003).  The Association 
of Project Management (APM) suggests that partnerships may present organisations with 
opportunities to pool resources and expertise, and to increase value while spreading risk (APM, 
2009). Jacobson and Roth (2014) articulate the view that partnerships are a good platform for 
engagement, whilst Naoum (2003) propagates them as a vehicle for the development of inter-
organisational trust and long-term relationships. Several authors share the view that 
collaborations offer the possibility of “win-win” benefits when the participating parties have 
shared objectives (Austin, 2000; Child and Faulkner, 1998; Langford and Murray, in Morris 
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and Pinto, 2004; Naoum, 2003), and Gray (1989) proposes a view that the quality of project 
outputs is improved by interagency partnership due to the deployment of diverse and 
complementary capabilities. 
 
In the UK, collaboration has been a major component of the government’s agenda to modernise 
the public sector, particularly in healthcare (Wildridge et al., 2004).  However, as noted by the 
Audit Commission (1998), it is important to remember that there should not be an assumption 
that partnership working is guaranteed to be a good thing, and Mattessich et al. (2001) warn 
that collaboration is not necessarily always the ideal way to address issues and accomplish 
tasks. Nevertheless, the literature provides a reasonably homogeneous view that collaboration 
on the whole is a positive undertaking that can offer a wide range of benefits to all participating 
parties. The academic literature regarding public-private collaborations in healthcare is very 
limited; available material tends to be confined to partnerships linked to financing and building 
healthcare estate (Healthcare UK, 2013; Holden, 2009), or the R&D environment (Chataway 
et al., 2012). This raises questions around the potential validity of the available partnership 
literature in this particular context. Further, this uniqueness is underscored by an ideological 
polarisation of the protagonists in public-private partnerships, with the pharmaceutical 
company operating within a commercial capitalist model and their NHS partner within a 
publicly funded socialised healthcare model. Therefore, it is the intent of this paper to evaluate 
and add new insights into an area of partnership that has thus far been little explored. 
  
3. Research Methodology 
 
The research adopted quantitative and qualitative approaches to collect data from a large 
pharmaceutical organisation in the UK. The first research method utilised was to examine 
documents already in existence and access data considered broad and independent from 
potential biases, Rabinovich and Cheon (2011). The quantitative data from these secondary 
sources was assimilated with information from the literature search and used as a platform for 
a focus group consisting of the organisation’s senior management. The purpose of the focus 
group was to encourage people to discuss their feelings and opinions about collaborative 
projects, and accumulate tacit and explicit knowledge that informed decisions when defining 
the degree of Joint Working capabilities required (Nonaka and Takeuchi, 1995). The subjects 
participating in the focus group were given information sheets regarding the research project, 
and each individual signed an informed consent form.   
 
The next technique used was interviews to collect qualitative data to interpret the opinion and 
values of those interviewed (Davis and Hughes, 2014; Merriam, 1998). The interviews were 
undertaken on a voluntary basis, and participants were given information sheets regarding the 
interview process and the research project, and each individual signed an informed consent 
form. In order to represent current practice these semi-structured interviews were undertaken 
with four individuals; two of these participants had undertaken Joint Working projects in the 
last two year, and two had not. The rationale for the relatively small sample size was that the 
information discovered would be in-depth and qualitative in nature, and also reflect the fact 
that the organisation had only completed a handful of Joint Working initiatives.   
 
The final technique deployed was the use of questionnaires, which senior management 
encouraged twenty-five senior managers to complete and consequently response rates were 
exceptional and served to eliminate ‘response bias’, whereby only the opinions of those 
motivated to participate are taken into consideration (Blair et al., 2014). The questionnaire was 
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designed with closed response questions that elicited greater conformity and enabled ease of 
measurement and comparison within and between responder groups (Gray, 2014; Yin, 2009).   
 
4. Findings 
 
4.1 Secondary Research 
 
Information gathered through secondary research provided evidence that demand exists within 
the industry to explore Joint Working projects, especially where the deliverables are based on 
infrastructure or of a digital nature. Documents accessed and analysed confirmed the success 
of pharmaceutical organisations’ efforts to commission innovative projects that challenge the 
conventional compliance doctrine and require stretching the boundaries of collaborations, and 
thereby provide a useful benchmark of where organisations sit on the Joint Working adoption 
curve.  
 
4.2 Focus Group 
 
The focus group identified a broad range of benefits, segregated as tangible and intangible, that 
organisations could realise through collaborative partnering. Relatively easily measurable 
factors such as ‘data’ and ‘job satisfaction scores’ were regarded as tangible benefits, as they 
are quantifiable and valuable to the company, and the presence of these elements could offer a 
reasonably straightforward justification for organisational commitment to a Joint Working 
project. The group also identified a number of intangible benefits, factors that although 
challenging to articulate and quantify, are nonetheless entirely appropriate as descriptors to 
justify Joint Working project participation. The essential finding from the group’s analysis of 
benefits was that transparent and assertive disclosure regarding the value the organisation 
anticipated realising from Joint Working would be critical if improved organisational capability 
to work in partnership is desired.  
 
4.3 Interviews 
 
The interviewees offered a number of attributes within the pharmaceutical industry that act to 
enable collaboration.  Individual confidence to competently execute projects and a thorough 
understanding of the paperwork and procedures required to implement Joint Working were 
specified as particularly important. Internal constraints to Joint Working were identified as: 
need to prioritise time on achieving clinical access for new pharmaceutical products; 
administrative burden associated with the paperwork needed to undertake Joint Working was 
considered a disincentive; lack of project management competencies among peer group; and 
an insular corporate attitude and no clear route to investment for collaborative projects.  
 
4.4 Survey 
 
The specific elements the questionnaire covered were communication, integrity, leadership, 
resourcefulness, teamwork and negotiation within Joint Working projects. The responses to the 
‘people’ competencies were remarkably consistent and relatively high across all six of these 
elements. Questions regarding resourcefulness and negotiation received the lowest mean 
scores, and communication received the highest mean score. The two elements within this area 
of competency, namely resourcefulness and negotiation, are worthy of further evaluation due 
to the high degree with which they are inter-related with other project management 
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competencies. Resourcefulness encompasses entrepreneurship and creativity, and the evidence 
suggests that such skills could enhance a practitioner’s ability to operationalise corporate 
strategy, take the initiative, and identify risk and opportunities. Similarly, the ‘negotiation’ 
element shares a large number of highly significant inter-connections with a wide array of other 
relevant competencies, and responses are very closely correlated to strategy, integrity, 
leadership, and teamwork. These significant inter-relationships suggest that as practitioners' 
confidence in their ability to negotiate increases, so too does the ability to integrate NHS and 
organisational strategy, and their willingness to proactively promote sustainability in their 
projects.  Similarly, increased negotiation ability is also associated with increased confidence 
in taking initiative and coming up with new ideas, and when working in a group actively 
encouraging people to contribute their own ideas. Consequently, any training initiative 
designed to holistically improve practitioner competencies should focus on ‘resourcefulness’ 
and ‘negotiation’ due to the promising level of influence they are likely to provoke among a 
range of other competence elements. 
 
5. Conclusions 
 
The evidence from both secondary and primary sources reiterate optimism that Joint Working 
offers substantial “win-win” benefits for patients and all project partners. The findings of this 
research suggest that potential benefits of engagement in partnering with the pharmaceutical 
industry exist but are generally not well recognised by all partners. The uptake of Joint Working 
is exceptionally low, with the fifteen largest pharmaceutical companies initiating just forty-
three projects in the UK in 2015. The benefits offered by the focus group participants and 
interviewees were almost identical in content and emphasis. The strongest factors articulated 
were the establishment of relationships with key personnel in the health service, and significant 
gains for organisations in regard to reputation and trust with their public-sector partners. The 
results from the survey also confirm that field-based practitioners in organisations strongly 
believe that Joint Working provides an opportunity for them to acquire deep customer insight. 
In addition, the participants in the focus group and interviews also stated a number of benefits 
from Joint Working are quantifiable, and as such may satisfy demands from organisations for 
returns from partnership that have an easily measurable value. This comprehensive range of 
benefits that would appear to represent a compelling rationale for enhanced capability in Joint 
Working. 
 
6. Future Work 
 
The findings of the pilot study form the basis of future work to be done, and feedback received 
at the conference will help strengthen and further develop the theoretical concepts and 
assumptions of this paper. Access is being secured to conduct empirical research with other 
pharmaceutical organisations implementing Joint Working projects.  
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